Literature DB >> 34891084

Epigenetic control of the Epstein-Barr lifecycle.

Rui Guo1, Benjamin E Gewurz2.   

Abstract

Epstein-Barr virus (EBV) infects 95% of adults worldwide, causes infectious mononucleosis, is etiologically linked to multiple sclerosis and is associated with 200 000 cases of cancer each year. EBV manipulates host epigenetic pathways to switch between a series of latency programs and to reactivate from latency in order to colonize the memory B-cell compartment for lifelong infection and to ultimately spread to new hosts. Here, we review recent advances in the understanding of epigenetic mechanisms that control EBV latency and lytic gene expression in EBV-transformed B and epithelial cells. We highlight newly appreciated roles of DNA methylation epigenetic machinery, host histone chaperones, the Hippo pathway, m6A RNA modification and nonsense mediated decay in control of the EBV lifecycle.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Mesh:

Year:  2021        PMID: 34891084      PMCID: PMC9112224          DOI: 10.1016/j.coviro.2021.11.013

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.121


  76 in total

1.  Early events in Epstein-Barr virus infection of human B lymphocytes.

Authors:  C Alfieri; M Birkenbach; E Kieff
Journal:  Virology       Date:  1991-04       Impact factor: 3.616

2.  Genome-wide analysis of host-chromosome binding sites for Epstein-Barr Virus Nuclear Antigen 1 (EBNA1).

Authors:  Fang Lu; Priyankara Wikramasinghe; Julie Norseen; Kevin Tsai; Pu Wang; Louise Showe; Ramana V Davuluri; Paul M Lieberman
Journal:  Virol J       Date:  2010-10-07       Impact factor: 4.099

3.  Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.

Authors:  Helen E Heslop; Karen S Slobod; Martin A Pule; Gregory A Hale; Alexandra Rousseau; Colton A Smith; Catherine M Bollard; Hao Liu; Meng-Fen Wu; Richard J Rochester; Persis J Amrolia; Julia L Hurwitz; Malcolm K Brenner; Cliona M Rooney
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

4.  B Cell Receptor Activation and Chemical Induction Trigger Caspase-Mediated Cleavage of PIAS1 to Facilitate Epstein-Barr Virus Reactivation.

Authors:  Kun Zhang; Dong-Wen Lv; Renfeng Li
Journal:  Cell Rep       Date:  2017-12-19       Impact factor: 9.423

5.  Methylation profiling of Epstein-Barr virus immediate-early gene promoters, BZLF1 and BRLF1 in tumors of epithelial, NK- and B-cell origins.

Authors:  Lili Li; Xianwei Su; Gigi Ching Gee Choi; Ya Cao; Richard F Ambinder; Qian Tao
Journal:  BMC Cancer       Date:  2012-03-29       Impact factor: 4.430

6.  DNA methylation profiling in human B cells reveals immune regulatory elements and epigenetic plasticity at Alu elements during B-cell activation.

Authors:  Anne Y Lai; Deepak Mav; Ruchir Shah; Sara A Grimm; Dhiral Phadke; Katerina Hatzi; Ari Melnick; Cissy Geigerman; Steve E Sobol; David L Jaye; Paul A Wade
Journal:  Genome Res       Date:  2013-09-06       Impact factor: 9.043

7.  Epstein-Barr virus reprograms human B lymphocytes immediately in the prelatent phase of infection.

Authors:  Paulina Mrozek-Gorska; Alexander Buschle; Dagmar Pich; Thomas Schwarzmayr; Ron Fechtner; Antonio Scialdone; Wolfgang Hammerschmidt
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-24       Impact factor: 11.205

8.  A heterochromatin inducing protein differentially recognizes self versus foreign genomes.

Authors:  Eric M Burton; Ibukun A Akinyemi; Tiffany R Frey; Huanzhou Xu; Xiaofan Li; Lai Jing Su; Jizu Zhi; Michael T McIntosh; Sumita Bhaduri-McIntosh
Journal:  PLoS Pathog       Date:  2021-03-17       Impact factor: 6.823

9.  BZLF1 governs CpG-methylated chromatin of Epstein-Barr Virus reversing epigenetic repression.

Authors:  Anne Woellmer; Jose M Arteaga-Salas; Wolfgang Hammerschmidt
Journal:  PLoS Pathog       Date:  2012-09-06       Impact factor: 6.823

10.  Hippo signaling effectors YAP and TAZ induce Epstein-Barr Virus (EBV) lytic reactivation through TEADs in epithelial cells.

Authors:  Nicholas Van Sciver; Makoto Ohashi; Nicholas P Pauly; Jillian A Bristol; Scott E Nelson; Eric C Johannsen; Shannon C Kenney
Journal:  PLoS Pathog       Date:  2021-08-02       Impact factor: 6.823

View more
  6 in total

1.  Methionine metabolism controls the B cell EBV epigenome and viral latency.

Authors:  Rui Guo; Jin Hua Liang; Yuchen Zhang; Michael Lutchenkov; Zhixuan Li; Yin Wang; Vicenta Trujillo-Alonso; Rishi Puri; Lisa Giulino-Roth; Benjamin E Gewurz
Journal:  Cell Metab       Date:  2022-09-06       Impact factor: 31.373

2.  Editorial overview: 2022 "Virus-Host Interaction" section of Current Opinion in Virology.

Authors:  Michaela U Gack; Susan C Baker
Journal:  Curr Opin Virol       Date:  2022-05-23       Impact factor: 7.121

3.  The Potential for EBV Vaccines to Prevent Multiple Sclerosis.

Authors:  Peter A Maple; Alberto Ascherio; Jeffrey I Cohen; Gary Cutter; Gavin Giovannoni; Claire Shannon-Lowe; Radu Tanasescu; Bruno Gran
Journal:  Front Neurol       Date:  2022-06-24       Impact factor: 4.086

Review 4.  Epstein-Barr virus and multiple sclerosis.

Authors:  Samantha S Soldan; Paul M Lieberman
Journal:  Nat Rev Microbiol       Date:  2022-08-05       Impact factor: 78.297

Review 5.  The roles of DNA methylation on the promotor of the Epstein-Barr virus (EBV) gene and the genome in patients with EBV-associated diseases.

Authors:  Linlin Zhang; Ran Wang; Zhengde Xie
Journal:  Appl Microbiol Biotechnol       Date:  2022-06-28       Impact factor: 5.560

6.  The Role of Codon Usage, tRNA Availability, and Cell Proliferation in EBV Latency and (Re)Activation.

Authors:  Darja Kanduc
Journal:  Glob Med Genet       Date:  2022-09-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.